Biomarker Research

Article	Citations
Development and validation of predictive models combining cell-Free DNA motifs and protein biomarkers for early detection of esophageal squamous cell carcinoma and precancerous lesion	175
CardioAtlas: deciphering the single-cell transcriptome landscape in cardiovascular tissues and diseases	165
Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study	157
Emerging therapeutic agents in multiple myeloma: highlights from the 2024 ASH annual meeting	146
Identification of GRIN2D as a novel therapeutic target in pancreatic ductal adenocarcinoma	134
Circulating Tumor DNA from Ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patients	129
The spatial impact of a Western diet in enriching Galectin-1-regulated Rho, ECM, and SASP signaling in a novel MASH-HCC mouse model	122
Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors	110
Skin-permeable gold nanoparticles with modifications azelamide monoethanolamine ameliorate inflammatory skin diseases	97
The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma	92
Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer	86
Exosomal PSM-E inhibits macrophage M2 polarization to suppress prostate cancer metastasis through the RACK1 signaling axis	86
Mitochondrial transfer in hematological malignancies	85
Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology	83
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes	81
Dynamic changes of bone microarchitecture and volumetric mineral density assessed by HR-pQCT in patients with cervical cancer after concurrent chemoradiotherapy: a prospective study	81
p53 biology and reactivation for improved therapy in MDS and AML	78
Copper homeostasis and copper-induced cell death in tumor immunity: implications for therapeutic strategies in cancer immunotherapy	77
Unveiling the potential of CLL-1: a promising target for AML therapy	76
Donor T cells for CAR T cell therapy	72
A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma	71
Therapeutic targeting of PFKFB3 and PFKFB4 in multiple myeloma cells under hypoxic conditions	71
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends	68
Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells	68
The overlooked trio: sleep duration, sampling time and physical exercise alter levels of olink-assessed blood biomarkers of cardiovascular risk	68

From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy	67
Monocyte-macrophages modulate intestinal homeostasis in inflammatory bowel disease	67
Correction: Manipulation of cancer cell pyroptosis for therapeutic approaches: challenges and opportunities	66
Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer	66
Multiple regulatory events contribute to a widespread circular RNA downregulation in precancer and early stage of colorectal cancer development	65
Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics	63
Identification of urinary bacterial genes as biomarkers for non-invasive diagnosis of renal lupus	63
Dysregulation of plasma circulating microRNAs in all-cause and cause-specific cancers: the Rotterdam Study	61
Proteomic and histopathologic profiling reveal molecular features and clinical biomarkers of coronary atherosclerosis	59
The role of BATF in immune cell differentiation and autoimmune diseases	59
Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients	58
Targeting interleukin-1β and inflammation in lung cancer	57
STAT3–mediated up-regulation of DAB2 via SRC-YAP1 signaling axis promotes Helicobacter pylori-driven gastric tumorigenesis	57
The role and metabolic adaptations of neutrophils in premetastatic niches	56
Correction: Long non-coding RNA SLC25A21-AS1 inhibits the development of epithelial ovarian cancer by specifically inducing PTBP3 degradation	54
RUNX1 promotes angiogenesis in colorectal cancer by regulating the crosstalk between tumor cells and tumor associated macrophages	54
The involvement of krüppel-like transcription factor 2 in megakaryocytic differentiation induction by phorbol 12-myrestrat 13-acetate	52
Oncogenic ACSM6 impairs CD8+ T cell-based immune response in bladder cancer	51
The methyltransferase-like proteins as core regulators of nucleic acid modifications and post-translation modification of proteins in disease pathogenesis and therapeutic implications	48
Immunophenotypic analysis on circulating T cells for early diagnosis of lung cancer	48
Long-term kinetics of proviral load in HTLV-1 carriers: defining risk for the development of adult T-cell leukemia/lymphoma	48
Glycochenodeoxycholic acid promotes hepatocarcinogenesis by inducing hepatic progenitor cell differentiation into cancer-associated fibroblasts via sphingosine-1-phosphate receptor 2 signalling	46
BRD4: an effective target for organ fibrosis	46
Transcriptomic analysis of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals distinct subgroups and precision therapy opportunities	45
Development of a bispecific antibody that inhibits EGFR and B7H3 in NSCLC	44
Whole genome and RNA sequencing analyses for 254 Taiwanese hepatocellular carcinomas	44
Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma	43
Disulfidptosis decoded: a journey through cell death mysteries, regulatory networks, disease paradigms and future directions	43
Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy	43
Correction: Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential	42
Comparison of proton therapy and photon therapy for early-stage non-small cell lung cancer: a meta-analysis	41
Mega-scale single-cell profiling reveals novel biomarkers associated with acute GvHD after allogeneic hematopoietic stem cell transplantation	41
Advances in measurable residual disease assessment for acute myeloid leukemia: from cytogenetics and molecular biology to assessment of the methylation pattern and surface-enhanced Raman scattering as	41
Correction: Pharmacokinetics of post-transplant cyclophosphamide and its associations with clinical outcomes in pediatric haploidentical hematopoietic stem cell transplantation	40
Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis	39
The essential roles of FXR in diet and age influenced metabolic changes and liver disease development: a multi-omics study	38
Updates on CAR T cell therapy in multiple myeloma	38
Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential	38
Intratumor microbiome in cancer progression: current developments, challenges and future trends	37
Functions and mechanisms of lncRNA MALAT1 in cancer chemotherapy resistance	36
Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis	35
Current advances and future perspectives on the functional roles and clinical implications of circular RNAs in esophageal squamous cell carcinoma: more influential than expected	35
Immune cells-derived exosomes function as a double-edged sword: role in disease progression and their therapeutic applications	35
Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors	34
The importance of critically short telomere in myelodysplastic syndrome	33
High-throughput LDI MS technology decodes the distinct metabolic landscape of prostate cancer in a large-scale cohort	32
Histamine N-methyltransferase (HNMT) as a potential auxiliary biomarker for predicting adaptability to anti-HER2 drug treatment in breast cancer patients	32
Fatty acid metabolism shapes immune responses in chronic lymphocytic leukemia	32
Single-cell sequencing technology in renal cancer: insights into tumor biology and clinical application	32
Identification of a miRNAs signature as potential biomarker of mesenchymal phenotype in neuroblastoma patients	31

Soluble PD-L1 as a novel biomarker predicts poor outcomes and disease progression in de novo myelodysplastic syndromes	31
Single-cell RNA sequencing identifies a subtype of FN1 + tumor-associated macrophages associated with glioma recurrence and as a biomarker for immunotherapy	30
Adipose-derived stem cell exosomes: mechanisms and therapeutic potentials in wound healing	30
Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer	30
Analyzing PKC Gamma (+ 19,506 A/G) polymorphism as a promising genetic marker for HCV-induced hepatocellular carcinoma	30
Targeting cGAS-STING pathway for reprogramming tumor-associated macrophages to enhance anti-tumor immunotherapy	29
Structures and biological functions of zinc finger proteins and their roles in hepatocellular carcinoma	29
Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer	29
MORF4L2 induces immunosuppressive microenvironment and immunotherapy resistance through GRHL2/MORF4L2/H4K12Ac/CSF1 axis in triple-negative breast cancer	29
Combined TP53 status in tumor-free resection margins and circulating microRNA profiling predicts the risk of locoregional recurrence in head and neck cancer	29
Targeting serine-glycine-one-carbon metabolism as a vulnerability in cancers	29
Imaging biomarkers for clinical applications in neuro-oncology: current status and future perspectives	29
Tobacco smoking associates with NF1 mutations exacerbating survival outcomes in gliomas	28
Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives	28
Targeting RPS6KC1 to overcome enzalutamide resistance in prostate cancer	27
FGL1 and FGL2: emerging regulators of liver health and disease	27
EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives	27
Lysine methylation modifications in tumor immunomodulation and immunotherapy: regulatory mechanisms and perspectives	27
Plasma proteomics uncovers divergent molecular signatures in ischemic stroke and intracerebral hemorrhage	26
A plasma 9-microRNA signature for lung cancer early detection: a multicenter analysis	26
New cell sources for CAR-based immunotherapy	26
Tumor-specific MHC-II guides anthracycline exemption and immunotherapy benefit in breast cancer	26
RNA epigenetic modifications as dynamic biomarkers in cancer: from mechanisms to clinical translation	26
Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma	26
NLRP4 unlocks an NK/macrophages-centered ecosystem to suppress non-small cell lung cancer	26
Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool	25
Prevalence and clinical significance of Claudin-3 expression in cancer: a tissue microarray study on 14,966 tumor samples	25
Extracellular matrix: unlocking new avenues in cancer treatment	25
Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed	25
Association of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States	25
Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics	25
Functional heterogeneity of cancer-associated fibroblasts with distinct neoadjuvant immunotherapy plus chemotherapy response in esophageal squamous cell carcinoma	25
T cells in cancer: mechanistic insights and therapeutic advances	24
Association between circulating ECM-associated molecules and cardiovascular outcomes in hemodialysis patients: a multicenter prospective cohort study	24
Application of double-negative T cells in haematological malignancies: recent progress and future directions	24
HDAC7 induction combined with standard-of-care chemotherapy provides a therapeutic advantage in t(4;11) infant B-cell acute lymphoblastic leukemia	24
S100A9 as a potential novel target for experimental autoimmune cystitis and interstitial cystitis/bladder pain syndrome	24
Challenges and advances for huntingtin detection in cerebrospinal fluid: in support of relative quantification	24
Nanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs	23
EIF4A3-induced Circ_0001187 facilitates AML suppression through promoting ubiquitin-proteasomal degradation of METTL3 and decreasing m6A modification level mediated by miR-499a-5p/RNF113A pathway	23
METTL3 facilitates immunosurveillance by inhibiting YTHDF2-mediated NLRC5 mRNA degradation in endometrial cancer	23
Targeting TIGIT for cancer immunotherapy: recent advances and future directions	22
Targeting NOX2 and glycolytic metabolism as a therapeutic strategy in acute myeloid leukaemia	22
USP21-EGFR-Lyn axis drives NSCLC progression and therapeutic potential of USP21 inhibition	22
Correction: CRISPR/Cas-based CAR-T cells: production and application	22
Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies	22
The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer	21
MiRNAs as potential therapeutic targets and biomarkers for non-traumatic intracerebral hemorrhage	21
The multifaceted roles of cathepsins in immune and inflammatory responses: implications for cancer therapy, autoimmune diseases, and infectious diseases	21
Human induced-T-to-natural killer cells have potent anti-tumour activities	21
SRTdb: an omnibus for human tissue and cancer-specific RNA transcripts	21
TUG1: a potential endogenous reference gene for long noncoding RNA quantification in blood-based studies	21
Microbiome multi-omics analysis reveals novel biomarkers and mechanisms linked with CD etiopathology	21
A germline FLT3 variant in aplastic anemia	20
Long noncoding RNA LIPH-4 promotes esophageal squamous cell carcinoma progression by regulating the miR-216b/IGF2BP2 axis	20
Harnessing multi-omics approaches to decipher tumor evolution and improve diagnosis and therapy in lung cancer	20
Single-cell multi-omics analysis identifies SPP1+ macrophages as key drivers of ferroptosis-mediated fibrosis in ligamentum flavum hypertrophy	20
PCSK9 in T-cell function and the immune response	20
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted	20
THSD4 is a novel mediator of T cell exclusion and anti-PD-1 resistance in hormone receptor-positive breast cancer	20
The LILRB family in hematologic malignancies: prognostic associations, mechanistic considerations, and therapeutic implications	19
MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression	19
Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer	19
High expression of TMEM244 is associated with poor overall survival of patients with T-cell lymphoma	19
Piwi-interacting RNA 775 (piR-775) predicts favorable prognosis and regulates cell cycle and DNA damage response pathways in breast cancer	19
Long non-coding RNA PWRN4 associated with post-SVR hepatocellular carcinoma: a genome-wide association study	18
Immune cell profiling supports early prediction of sepsis-associated acute kidney disease using a decision tree algorithm	18
PTK2 is a potential biomarker and therapeutic target for EGFR- or TLRs-induced lung cancer progression via the regulation of the cross-talk between EGFR- and TLRs-mediated signals	18
Cervical cancer heterogeneity: a constant battle against viruses and drugs	18
The clinical application of ctDNA to predict response to neoadjuvant chemoradiotherapy in patients with locally-advanced rectal cancer	18
Crosstalk between lactylation and RNA modifications in tumorigenesis: mechanisms and therapeutic implications	18
The significant others of aurora kinase a in cancer: combination is the key	18
Oncogenic alterations in advanced NSCLC: a molecular super-highway	18
Correction: LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/ miR-324-3p-SIRT5 axis in lung adenocarcinoma	17
Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects	17
Toll-like receptor 3: a double-edged sword	17
The role of ncRNAs in neuroblastoma: mechanisms, biomarkers and therapeutic targets	17
HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma	17
Noninvasive biomarkers implicated in urea and TCA cycles for metabolic liver disease	17
The detection, biological function, and liquid biopsy application of extracellular vesicle-associated DNA	17

Identification of exosomal microRNA panel as diagnostic and prognostic biomarker for small cell lung cancer	16
Blood and urine biomarkers of disease progression in IgA nephropathy	16
Ribosome profiling: a powerful tool in oncological research	16
Circulating long non-coding RNAs detection after heart transplantation and its accuracy in the diagnosis of acute cardiac rejection	16
Targeted inhibition of Ninjurin2 promotes chemosensitivity in chemoresistant gastric cancer by suppressing cancer-initiating cells	16
LncRNA AC006064.4–201 serves as a novel molecular marker in alleviating cartilage senescence and protecting against osteoarthritis by destabilizing CDKN1B mRNA via interacting with PTBP1	16
MACC1 revisited – an in-depth review of a master of metastasis	16
The role of pyroptosis in modulating the tumor immune microenvironment	16
Correction: Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements	16
Vitamin D activates FBP1 to block the Warburg effect and modulate blast metabolism in acute myeloid leukemia	16
Deciphering mechanical cues in the microenvironment: from non-malignant settings to tumor progression	16
The emerging landscape of exosomal CircRNAs in solid cancers and hematological malignancies	16
Phenomic landscape and pharmacogenomic implications for HLA region in a Taiwan Han Chinese population	16
High IL1R1 expression predicts poor survival and benefit from stem cell transplant in intermediate-risk acute myeloid leukemia from the Leucegene cohort	16
Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy	16
Therapeutic landscape of ovarian cancer: recent advances and emerging therapies	15
IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia	15
Simultaneous inhibition of FAK and ROS1 synergistically repressed triple-negative breast cancer by upregulating p53 signalling	15
Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients	15
Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma	15
TRPM channels in human cancers: regulatory mechanism and therapeutic prospects	15
Tumor microenvironment and immunotherapy for triple-negative breast cancer	15
Antileukemic potential of methylated indolequinone MAC681 through immunogenic necroptosis and PARP1 degradation	15
Exploring non-invasive precision treatment in non-small cell lung cancer patients through deep learning radiomics across imaging features and molecular phenotypes	14
Clinical stabilization of a highly refractory acute myeloid leukaemia under individualized treatment with immune response modifying drugs by in vivo generation of dendritic cells of leukaemic origin (	14
Review immune response of targeting CD39 in cancer	14
Correction: Comprehensive analysis of peroxiredoxins expression profiles and prognostic values in breast cancer	14
Comprehensive plasma metabolomics profiling develops diagnostic biomarkers of obstructive hypertrophic cardiomyopathy	14
Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer	14
Leveraging oncovirus-derived antigen against the viral malignancies in adoptive cell therapies	13
Sintilimab for the treatment of non-small cell lung cancer	13
Exosome derived from tumor-associated macrophages: biogenesis, functions, and therapeutic implications in human cancers	13
CRISPR/Cas-based CAR-T cells: production and application	13
Pharmacokinetics of post-transplant cyclophosphamide and its associations with clinical outcomes in pediatric haploidentical hematopoietic stem cell transplantation	13
Circulating tumor DNA for MRD detection in colorectal cancer: recent advances and clinical implications	13
Roles of posttranslational modifications in lipid metabolism and cancer progression	13
Gene therapy for polygenic or complex diseases	13
Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools	13
Biological roles of RNA m5C modification and its implications in Cancer immunotherapy	13
CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond	13
Serum metabolite signatures of cardiac function and morphology in individuals from a population-based cohort	12
Global, regional, and national burden of heart failure and its underlying causes, 1990–2021: results from the global burden of disease study 2021	12
Folate receptor 1 is a stemness trait-associated diagnostic and prognostic marker for hepatocellular carcinoma	12
Global surveillance of circulating microRNA for diagnostic and prognostic assessment of acute myocardial infarction based on the plasma small RNA sequencing	12
Biomarkers as targets for CAR-T/NK cell therapy in AML	12
The war between the immune system and the tumor - using immune biomarkers as tracers	12
A functional role of Ephrin type-B receptor 6 (EPHB6) in T-cell acute lymphoblastic leukemia	12
Clinical and structural insights into concurrent EGFR and MET exon 14 skipping mutations in NSCLC: a multi-center series	12
Detection of circulating tumor cells: opportunities and challenges	12
Correction: Vitamin D activates FBP1 to block the Warburg effect and modulate blast metabolism in acute myeloid leukemia	12
Deciphering metabolic heterogeneity in retinoblastoma unravels the role of monocarboxylate transporter 1 in tumor progression	12
Physio-pathological effects of N6-methyladenosine and its therapeutic implications in leukemia	12
Global burden of breast cancer and attributable risk factors in 204 countries and territories, from 1990 to 2021: results from the Global Burden of Disease Study 2021	12
LRG1, a novel serum biomarker for iMCD disease activity	12
Correction: A novel 3-miRNA network regulates tumour progression in oral squamous cell carcinoma	12
The role of platelets in cancer: from their influence on tumor progression to their potential use in liquid biopsy	12
Combination immunotherapy targeting LAG-3, PD-1 and STING suppresses hepatocellular carcinoma as monitored by LAG-3 targeted PET imaging	12
DeepMPTB: a vaginal microbiome-based deep neural network as artificial intelligence strategy for efficient preterm birth prediction	12
Integrative multi-omics analysis depicts the methylome and hydroxymethylome in recurrent bladder cancers and identifies biomarkers for predicting PD-L1 expression	12
Development and validation of an integrative 54 biomarker-based risk identification model for multi-cancer in 42,666 individuals: a population-based prospective study to guide advanced screening strat	11
Untargeted lipidomics reveals racial differences in lipid species among women	11
Integrating artificial intelligence in drug discovery and early drug development: a transformative approach	11
Current challenges and best practices for cell-free long RNA biomarker discovery	11
Phenotypic and metabolomic characteristics of mouse models of metabolic associated steatohepatitis	11
Competing endogenous RNA networks related to prognosis in chronic lymphocytic leukemia: comprehensive analyses and construction of a novel risk score model	11
Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma	11
Effect of regulatory cell death on the occurrence and development of head and neck squamous cell carcinoma	11
Heat shock proteins (HSPs) in non-alcoholic fatty liver disease (NAFLD): from molecular mechanisms to therapeutic avenues	11
Advances of cancer-associated fibroblasts in liver cancer	11
Deciphering the correlation between metabolic activity through 18F-FDG-PET/CT and immune landscape in soft-tissue sarcomas: an insight from the NEOSARCOMICS study	11
Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML	11
The application of Aptamer in biomarker discovery	11
The role of biomarkers in personalized immunotherapy	11
Lactate and lactylation: molecular insights into histone and non-histone lactylation in tumor progression, tumor immune microenvironment, and therapeutic strategies	10
Targeting myeloid cells for hematological malignancies: the present and future	10
Advancement in Multi-omics approaches for Uterine Sarcoma	10
The landscape overview of CD47-based immunotherapy for hematological malignancies	10
Harnessing natural killer cells for refractory/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective	10
Molecular network of metabolic reprogramming and precision diagnosis and treatment of hepatocellular carcinoma	10
Characterization of T-Cell receptor repertoire in immunoglobulin a nephropathy	10
Epigenetic signatures on plasma cell-free DNA to detect kidney allograft rejection in a non-invasive way: development of a 10-plex digital PCR assay	10
The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy	10
Bioinformatics tools and data resources for assay development of fluid protein biomarkers	10
Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications	10
Machine learning-based radiomics model: prognostic prediction and mechanism exploration in patients with endometrial cancer	10
KSR2-14–3-3ζ complex serves as a biomarker and potential therapeutic target in sorafenib-resistant hepatocellular carcinoma	10
The Musashi RNA-binding proteins in female cancers: insights on molecular mechanisms and therapeutic relevance	10
Single cell spatial profiling of FFPE splenic tissue from a humanized mouse model of HIV infection	10
Microfluidic biosensors for biomarker detection in body fluids: a key approach for early cancer diagnosis	10
MRI-based radiomic prognostic signature for locally advanced oral cavity squamous cell carcinoma: development, testing and comparison with genomic prognostic signatures	9
X-chromosome-linked miR-542-5p as a key regulator of sex disparity in rats with adjuvant-induced arthritis by promoting Th17 differentiation	9
Clinical translation of patient-derived tumour organoids- bottlenecks and strategies	9
Single cell analysis identified IFN signaling activation contributes to the pathogenesis of pediatric steroid-sensitive nephrotic syndrome	9
Lectins as potential tools for cancer biomarker discovery from extracellular vesicles	9
METTL1 promotes neuroblastoma development through m7G tRNA modification and selective oncogenic gene translation	9